Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

102 CEFEPIME
Erythema multiforme
Exanthems (1.8%)
Pruritus (1–10%)
(1993): Giamarellou H, J Antimicrob Chemother 32 Suppl B, 123
(2%)
(1993): Jauregui L+, J Antimicrob Chemother 32 Suppl B, 141
(1993): Mouton Y+, J Antimicrob Chemother 32 Suppl B, 133
(4%)
Rash (sic) (51%)
(2001): Mustafa MM+, Pediatr Infect Dis J 20(3), 362
(2000): Sheng WH+, J Microbiol Immunol Infect 33, 109
(1996): Holloway WJ+, Am J Med 100, 52S
(1995): Schrank JH+, Clin Infect Dis 20(1), 56
(1994): Okamoto MP+, Am J Hosp Pharm 51, 463
(1993): Barckow D+, J Antimicrob Chemother 32 Suppl B, 187
(1993): Giamarellou H, J Antimicrob Chemother 32 Suppl B, 123
(2%)
(1993): Mouton Y+, J Antimicrob Chemother 32 Suppl B, 133
(4%)
(1993): Newton ER+, J Antimicrob Chemother 32 Suppl B, 195
Stevens–Johnson syndrome
Toxic epidermal necrolysis
Urticaria (1.8%)
(1993): Mouton Y+, J Antimicrob Chemother 32 Suppl B, 133
(4%)
Mucosal
Oral candidiasis
Vaginitis (